Sorafenib targets and inhibits the oncogenic properties of endometrial cancer stem cells via the RAF/ERK pathway.

Stem Cell Res Ther · 2022 · PMC9166406 · PMID 35659728

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

not quite significantno p-value reported

5 C), the pERK/ERK ratio was higher in SP-ctrl than in MP-ctrl, but the difference was not quite significant (Additional file 6 : Fig.

also in 653 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.